Drug · CHEMBL53
APOMORPHINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. APOMORPHINE. Drugs and targets, record CHEMBL53. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL53
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| DRD2 | D2-like dopamine receptor | D2-like dopamine receptor agonist | AGONIST | https://conductscience.org/library/genes/1813 |
| DRD3 | D2-like dopamine receptor | D2-like dopamine receptor agonist | AGONIST | https://conductscience.org/library/genes/1814 |
| DRD4 | D2-like dopamine receptor | D2-like dopamine receptor agonist | AGONIST | https://conductscience.org/library/genes/1815 |
Source ChEMBL
Diseases11
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 11Source Open Targets
See all 11 diseasesTrials41
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02542696 | Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease | Phase 3 | 496 | 2023-11-22 | APL-130277 | Its name | ClinicalTrials.gov |
| NCT02469090 | Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease | Phase 3 | 141 | 2020-07-30 | APL-130277 | Its name | ClinicalTrials.gov |
| NCT01770145 | Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) | Phase 4 | 127 | 2015-09-07 | apomorphine | Its name | ClinicalTrials.gov |
| NCT03391882 | A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) | Phase 3 | 113 | 2022-12-16 | APL-130277, apomorphine | Its name | ClinicalTrials.gov |
| NCT03187301 | A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes | Phase 2 | 48 | 2020-08-10 | apomorphine | Its name | ClinicalTrials.gov |
| NCT02228590 | A Study to Examine APL-130277 in Patients With Parkinson's Disease | Phase 2 | 20 | 2020-07-30 | apl-130277 | Its name | ClinicalTrials.gov |
| NCT02549573 | Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN® | Phase 4 | 13 | 2018-01-12 | apomorphine | Its name | ClinicalTrials.gov |
| NCT03292016 | A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes | Phase 2 | 8 | 2020-08-13 | apomorphine | Its name | ClinicalTrials.gov |
| NCT00142545 | Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease | Phase 3 | 800 | apomorphine | Its name | ClinicalTrials.gov | |
| NCT02864004 | Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP) | Phase 3 | 134 | apomorphine | Its name | ClinicalTrials.gov |
1 to 10 of 41
See all 41 trialsComparisons in its trials1
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Apokyn Treatment Before Physical Therapy vs Apokyn Treatment Withheld Before Physical Therapy: serious adverse events | 1 of 6 | 0 of 7 | 13 | NCT02549573 |
Source Trial comparisons
Papers from its trials17
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Category Fluency | 1 | 0 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL53
GET https://conductscience.org/api/drugs/v1/CHEMBL53/trials?page=2